Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US6900245B2 · kind B2 · utility
0Cited by
10References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 3, 2003 |
| Grant date | May 31, 2005 |
| Priority date | — |
| Expiry date | Nov 3, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC30B7/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a pharmaceutical composition for treating or preventing obesity, comprising novel crystalline sibutramine methanesulfonate hemihydrate of formula (I). The crystalline sibutramine methanesulfonate hemihydrate according to the present invention has a much higher solubility in water, and enhanced stability under a high humidity/temperature condition, as compared with sibutramine hydrochloride monohydrate
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.